SEC Seeks Vaccine Manufacturer Input On Pediatric Stockpile Accounting
This article was originally published in The Pink Sheet Daily
Executive Summary
Securities & Exchange Commission regulations on revenue recognition are preventing childhood vaccine manufacturers from selling product to a government stockpile. Rep. Waxman declares support for a special exemption for vaccine makers.
You may also be interested in...
Stockpiled Vaccine Can Be Recognized As Revenue In Next Fiscal Year, Says SEC
The "unique" nature of vaccines sold for stockpiling allows companies to record revenue without meeting traditional requirements, according to an SEC guidance.
Stockpiled Vaccine Can Be Recognized As Revenue In Next Fiscal Year, Says SEC
The "unique" nature of vaccines sold for stockpiling allows companies to record revenue without meeting traditional requirements, according to an SEC guidance.
Sen. Gregg Requests HHS Report On Pediatric Vaccine Stockpile
A revenue recognition issue is causing the stockpile to shrink, the Budget Committee chairman tells HHS. The “overdue” report, which was called for in the fiscal year 2005 appropriations legislation, should address administrative or legislative solutions, he says.